Editorial: Drug-induced liver injury in clinical trials: As rare as hens teeth

Timothy J. Davern, Naga Chalasani

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Severe drug-induced liver injury is a relatively rare but important public health problem. Extrapolating the incidence of this problem from clinical treatment trials is confounded by a number of issues, including the relatively small size of clinical trials, exclusion criteria for study participation, and active surveillance for liver injury. Advances in understanding the pathogenesis of drug-induced liver injury, as well as its prevention and treatment, will likely require the identification and careful characterization of severe cases in the post-marketing, real-world setting as part of a concerted, multi-center, well-orchestrated effort. The Drug-Induced Liver Injury Network (DILIN) represents one example of such an effort.

Original languageEnglish (US)
Pages (from-to)1159-1161
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume104
Issue number5
DOIs
StatePublished - May 1 2009

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Editorial: Drug-induced liver injury in clinical trials: As rare as hens teeth'. Together they form a unique fingerprint.

  • Cite this